Compare Quantum Computing Inc (QUBT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantum Computing Inc vs Sanofi SA — how do they compare? Quantum Computing Inc trades at $7.92 (market cap $1.85B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 56.7× Quantum Computing Inc's market cap, and Sanofi SA pays a 5.53% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| QUBT | SNY | |
|---|---|---|
Market Cap | $1.85B | $104.85B |
Sector | Technology | Health |
52-Week High | $24.62 | $52.34 |
52-Week Low | $6.31 | $41.33 |
Enterprise Value | $871.49M | $121.38B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quantum Computing Inc. (QUBT) trades at $7.92, up 1.54% on the day, while technical indicators signal a bearish trend. The company reported minimal revenue of $682K in 2025 with a net loss of $18.67M, reflecting negative profit margins. Recent news highlights a shareholder investigation into potential fiduciary breaches, though some analysts remain optimistic about commercial growth prospects in quantum computing.
Despite a high analyst consensus price target of $26.00 and 75% buy ratings, QUBT faces significant financial risks including cash burn, negative earnings, and competitive pressures. The stock's outlook hinges on successful commercialization and revenue scaling, but current fundamentals suggest high volatility and speculative investment appeal.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
